BioMedNewsBreaks

ThursdayMar 31, 2022 12:58 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that the first visit has been conducted in a Cybin-sponsored feasibility study. The study will focus on evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies have had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By deploying the innovative Flow technology,…

Continue Reading

ThursdayMar 31, 2022 11:20 am

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Enters Agreement to Significantly Advance Technologies ‘Closer to the Clinic’

Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. Silo Pharma today announced its entry into an agreement with Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals. “This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic,” said Eric Weisblum, CEO of Silo Pharma. “These solutions have the potential to enhance the therapeutic effect of current…

Continue Reading

WednesdayMar 30, 2022 11:52 am

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Initiates Coverage with InvestorBrandNetwork

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has partnered with InvestorBrandNetwork (“IBN”) for its corporate communications. IBN is a multifaceted financial news and publishing company focused on private and public entities. Silo works to develop innovative solutions that address serious conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease and other rare neurological disorders. The company is committed to identifying and partnering with leading medical universities; SILO provides invaluable financial resources to develop safe therapeutic treatments while advancing research through clinical stage studies and trials and into…

Continue Reading

TuesdayMar 29, 2022 2:30 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, partnering to advance research and more. The company has partnered with Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University (“JHU”), to lead its planned placebo-controlled study evaluating the science and efficacy of MYCO-001, its lead psilocybin-based drug…

Continue Reading

TuesdayMar 29, 2022 12:15 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (“MDD”). According to the update, data from the studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the advancement toward an investigational new drug (“IND”) filing with the U.S. Food and Drug Administration (“FDA”) for a Phase 1/2a first-in-human clinical trial in patients with MDD. “The completion of these in vivo preclinical studies for CYB003 represents a…

Continue Reading

MondayMar 28, 2022 1:50 pm

BioMedNewsBreaks – Pono Capital Corp (NASDAQ: PONOU), Benuvia Inc. Enter Definitive Business Combination Agreement

Pono (NASDAQ: PONOU), a publicly traded special purpose acquisition company, and Benuvia, a leading drug developer and manufacturer of active pharmaceutical ingredients focused on cannabinoids, with a growing portfolio of drug products and intellectual property, announced entry into a definitive business combination agreement that will result, subject to the satisfaction or waiver of certain closing conditions, in Benuvia becoming a public company. According to the announcement, Benuvia will apply to be listed on the Nasdaq. “Benuvia has established a strong position in the pharmaceutical cannabinoid market with its intellectual property and manufacturing assets,” said Dustin Shindo, chief executive officer of…

Continue Reading

FridayMar 25, 2022 2:19 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Committed to Execute More Programs to Grow Market Reach and Product Portfolio

InMed Pharmaceuticals (NASDAQ: INM) President and CEO Eric A. Adams recently hosted a conference call and webcast in which he emphasized the company’s successful product diversification and strategic acquisition achievements. He expressed his optimism at the company’s expansion into the health and wellness sector as an ingredient supplier and the integration of BayMedica’s operations and team into its ongoing activities. A recent article reads: “While noting how recent product launches have allowed the company to top its revenue estimates, Mr. Adams was also keen to point out its ongoing commitment to launch even more products in the coming months. He…

Continue Reading

FridayMar 25, 2022 10:57 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved a key milestone. The milestones were identified in the Dec. 4, 2020, contribution agreement between Cybin and Adelia and include Year 1 Q4 (vi), Year 2 Q2 (ii), Year 2 Q2 (v) and Year 2, Q3 (iii). Others involved in the agreement include Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. According to the agreement, Adelia shareholders will be issued 90,546.0 Class B shares in Cybin; those shares are exchangeable…

Continue Reading

FridayMar 25, 2022 10:21 am

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming Maxim Group 2022 Virtual Growth Conference

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be attending and participating at this month’s Maxim Group 2022 Virtual Growth Conference. NMRD CEO Dr. Faz Chowdhury will be providing an overview of the company that will be available to view beginning on March 28, 2022, at 9 a.m. ET. In addition to his presentation, Chowdhury will be available to meet one-on-one with those attending the event. The three-day conference is scheduled for March 28–30, 2022. To view the full presentation, visit…

Continue Reading

ThursdayMar 24, 2022 2:11 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study will evaluate participants’ experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” Cybin’s Chief Executive Officer Doug Drysdale said in the press release. “Until now, our understanding of the psychedelic experience has been fairly subjective.…

Continue Reading